{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:14:54Z","timestamp":1788462894573,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203930\/B\/16\/Z"],"award-info":[{"award-number":["203930\/B\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203930\/B\/16\/Z"],"award-info":[{"award-number":["203930\/B\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Emer Casey Foundation"},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["18\/CRT\/6214"],"award-info":[{"award-number":["18\/CRT\/6214"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","award":["Clinician Research Leadership Award"],"award-info":[{"award-number":["Clinician Research Leadership Award"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"DOI":"10.1038\/s41431-026-02161-3","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:38:06Z","timestamp":1788460686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of BRCA1\/2 variants in an Ovarian Cancer Cohort: outcomes from a Nationwide Testing Program"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3587-4018","authenticated-orcid":false,"given":"Ciara S.","family":"McNevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Murchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Thodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9099-7462","authenticated-orcid":false,"given":"Cathal","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2425-5194","authenticated-orcid":false,"given":"Trudi","family":"McDevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni Deepa","family":"Kalachand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-7148","authenticated-orcid":false,"given":"Karen A.","family":"Cadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2161_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2161_CR2","unstructured":"(NCRI) NCRI. Cancer Factsheet Ovary (ICD-10 C56). (Registry NC. Cancer Factsheet Ovary 2018) 2020. Available from: https:\/\/www.ncri.ie\/sites\/ncri\/files\/factsheets\/Factsheet%20ovary.pdf."},{"key":"2161_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:16061.","journal-title":"Nat Rev Dis Prim"},{"key":"2161_CR4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria PJ, Bast RC Jr., Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668\u201379.","journal-title":"Nat Rev Cancer"},{"key":"2161_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137\u201354.","journal-title":"Cancer Discov"},{"key":"2161_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"2161_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","volume":"150","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150:85\u201391.","journal-title":"Gynecol Oncol"},{"key":"2161_CR8","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402\u201316.","journal-title":"JAMA"},{"key":"2161_CR9","unstructured":"Survelliance E, End Result Cancer Stat Facts: Ovarian Cancer 2019. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"2161_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1245\/s10434-022-12459-3","volume":"30","author":"J Glajzer","year":"2023","unstructured":"Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, et al. Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: a multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Ann Surgical Oncol. 2023;30:35\u201345.","journal-title":"Ann Surgical Oncol"},{"key":"2161_CR11","doi-asserted-by":"crossref","unstructured":"Takamatsu S, Yoshihara K, Baba T, Shimada M, Yoshida H, Kajiyama H, et al. Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study. Br J Cancer. 2023;128:1095\u2013104.","DOI":"10.1038\/s41416-022-02122-9"},{"key":"2161_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/em.22505","volume":"63","author":"C Shao","year":"2022","unstructured":"Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, et al. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ Mol Mutagen. 2022;63:308\u201316.","journal-title":"Environ Mol Mutagen"},{"key":"2161_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"2161_CR14","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"2161_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148\u201359.","journal-title":"Ann Oncol"},{"key":"2161_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0484-6","volume":"12","author":"A Gadducci","year":"2019","unstructured":"Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019;12:9.","journal-title":"J Ovarian Res"},{"key":"2161_CR17","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO Guideline. J Clin Oncol. 2020;38:1222\u201345.","journal-title":"J Clin Oncol"},{"key":"2161_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833\u201348.","journal-title":"Ann Oncol"},{"key":"2161_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35:248\u201366.","journal-title":"Ann Oncol"},{"key":"2161_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/cancers15020337","volume":"15","author":"S Sundar","year":"2023","unstructured":"Sundar S, Nordin A, Morrison J, Wood N, Ghaem-Maghami S, Nieto J, et al. British Gynaecological Cancer Society recommendations for evidence based, population data derived quality performance indicators for ovarian cancer. Cancers. 2023;15:2.","journal-title":"Cancers"},{"key":"2161_CR21","unstructured":"Kalachand R. Cancer Trials Ireland opens study to enable upfront and streamlined germline and somatic BRCA1\/2 mutation testing in women with ovarian cancer https:\/\/www.cancertrials.ie\/wp-content\/uploads\/2019\/05\/t-BRCA.pdf (Cancer Trials Ireland, 2019)."},{"key":"2161_CR22","unstructured":"(NCCP) NCCP. Guidance for medical oncologists on testing requirements by direct ordering to inform PARPi treatment options 2023. Available from: https:\/\/www.hse.ie\/eng\/services\/list\/5\/cancer\/profinfo\/medonc\/sactguidance\/guidance-for-medical-oncologists-on-testing-requirements-by-direct-ordering-to-inform-parpi-treatment-options.pdf."},{"key":"2161_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00137","volume":"7","author":"TY Sia","year":"2023","unstructured":"Sia TY, Maio A, Kemel YM, Arora KS, Gordhandas SB, Kahn RM, et al. Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer. JCO Precis Oncol. 2023;7:e2300137.","journal-title":"JCO Precis Oncol"},{"key":"2161_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/cancers13030532","volume":"13","author":"G Figlioli","year":"2021","unstructured":"Figlioli G, De Nicolo A, Catucci I, Manoukian S, Peissel B, Azzollini J, et al. Analysis of Italian BRCA1\/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. Cancers (Basel). 2021;13:3.","journal-title":"Cancers (Basel)"},{"key":"2161_CR25","doi-asserted-by":"publisher","first-page":"e0201086","DOI":"10.1371\/journal.pone.0201086","volume":"13","author":"A Kowalik","year":"2018","unstructured":"Kowalik A, Sio\u0142ek M, Kopczy\u0144ski J, Krawiec K, Kalisz J, Zi\u0119ba S, et al. BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1\/2 next-generation sequencing study. PloS one. 2018;13:e0201086 e.","journal-title":"PloS one"},{"key":"2161_CR26","doi-asserted-by":"publisher","first-page":"vi93","DOI":"10.1093\/annonc\/mdm234","volume":"18","author":"R Ferla","year":"2007","unstructured":"Ferla R, Cal\u00f2 V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol. 2007;18:vi93\u20138.","journal-title":"Ann Oncol"},{"key":"2161_CR27","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.3802\/jgo.2017.28.e61","volume":"28","author":"L Helpman","year":"2017","unstructured":"Helpman L, Zidan O, Friedman E, Kalfon S, Perri T, Ben-Baruch G, et al. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates. J Gynecol Oncol. 2017;28:e61.","journal-title":"J Gynecol Oncol"},{"key":"2161_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01767-x","volume":"29","author":"AA de Freitas Ribeiro","year":"2024","unstructured":"de Freitas Ribeiro AA, Junior NMC, Dos Santos LL. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario. Eur J Med Res. 2024;29:187.","journal-title":"Eur J Med Res"},{"key":"2161_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12089-w","volume":"24","author":"Z Wu","year":"2024","unstructured":"Wu Z, Zhang Q, Jin Y, Zhang X, Chen Y, Yang C, et al. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area. BMC Cancer. 2024;24:411.","journal-title":"BMC Cancer"},{"key":"2161_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1373\/clinchem.2016.263897","volume":"63","author":"K Neveling","year":"2017","unstructured":"Neveling K, Mensenkamp AR, Derks R, Kwint M, Ouchene H, Steehouwer M, et al. BRCA testing by single-molecule molecular inversion probes. Clin Chem. 2017;63:503\u201312.","journal-title":"Clin Chem"},{"key":"2161_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"2161_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/jmedgenet-2019-106759","volume":"57","author":"A Garrett","year":"2020","unstructured":"Garrett A, Callaway A, Durkie M, Cubuk C, Alikian M, Burghel GJ, et al. Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. J Med Genet. 2020;57:829\u201334.","journal-title":"J Med Genet"},{"key":"2161_CR33","unstructured":"CanVar C CanVIG-UK Gene Specific Recommendations 2024 [cited 2025 9\/9\/25]. Available from: https:\/\/www.cangene-canvaruk.org\/gene-specific-recommendations."},{"key":"2161_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41416-022-01773-y","volume":"127","author":"RD Morgan","year":"2022","unstructured":"Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, et al. BRCA1\/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing? Br J Cancer. 2022;127:163\u20137.","journal-title":"Br J Cancer"},{"key":"2161_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/jmedgenet-2016-103902","volume":"53","author":"I Plaskocinska","year":"2016","unstructured":"Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, et al. New paradigms for BRCA1\/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet. 2016;53:655\u201361.","journal-title":"J Med Genet"},{"key":"2161_CR36","unstructured":"Office ICS. Census of Population 2011, Census of Population 2016 \u2013 Profile 8 Irish Travellers, Ethnicity and Religion 2017. updated 12 October 2017. Available from: https:\/\/www.cso.ie\/en\/releasesandpublications\/ep\/p-cp8iter\/p8iter\/p8rnc\/ 2012."},{"key":"2161_CR37","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/1055-9965.2078.13.12","volume":"13","author":"AS Whittemore","year":"2004","unstructured":"Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, et al. Prevalence of BRCA1 mutation carriers among U.S. non-hispanic whites. Cancer Epidemiol Biomark Prev. 2004;13:2078\u201383.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2161_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/928562","volume":"2013","author":"F Karami","year":"2013","unstructured":"Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int. 2013;2013:928562.","journal-title":"Biomed Res Int"},{"key":"2161_CR39","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/ijgc-2022-004211","volume":"33","author":"RD Morgan","year":"2023","unstructured":"Morgan RD, Clamp AR, Barnes BM, Timms K, Schlecht H, Yarram-Smith L, et al. Homologous recombination deficiency in newly diagnosed FIGO stage III\/IV high-grade epithelial ovarian cancer: a multi-national observational study. Int J Gynecol Cancer. 2023;33:1253\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"2161_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10689-022-00313-0","volume":"22","author":"TP McVeigh","year":"2023","unstructured":"McVeigh TP, Sweeney KJ, Brennan DJ, McVeigh UM, Ward S, Strydom A, et al. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and\/or ovarian cancer in three tertiary Cancer Centres in Ireland. Fam Cancer. 2023;22:135\u201349.","journal-title":"Fam Cancer"},{"key":"2161_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.breast.2011.04.005","volume":"20","author":"PA Carroll","year":"2011","unstructured":"Carroll PA, Nolan C, Clarke R, Farrell M, Gleeson N, Boyle T, et al. Surgical management of an Irish cohort of BRCA-mutation carriers. Breast. 2011;20:419\u201323.","journal-title":"Breast"},{"key":"2161_CR42","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41431-020-0692-y","volume":"28","author":"N Flaum","year":"2020","unstructured":"Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, et al. Mainstreaming germline BRCA1\/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Eur J Hum Genet. 2020;28:1541\u20137.","journal-title":"Eur J Hum Genet"},{"key":"2161_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.annonc.2022.01.006","volume":"33","author":"P Terraf","year":"2022","unstructured":"Terraf P, Pareja F, Brown DN, Ceyhan-Birsoy O, Misyura M, Rana S, et al. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. Ann Oncol. 2022;33:426\u201333.","journal-title":"Ann Oncol"},{"key":"2161_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/gcc.23150","volume":"62","author":"MA Jones","year":"2023","unstructured":"Jones MA, Timms KM, Hatcher S, Cogan ES, Comeaux MS, Perry M, et al. The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20000 ovarian tumors identified using next-generation sequencing. Genes Chromosomes Cancer. 2023;62:589\u201396.","journal-title":"Genes Chromosomes Cancer"},{"key":"2161_CR45","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/cancers13174344","volume":"13","author":"D Chandrasekaran","year":"2021","unstructured":"Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, et al. Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study. Cancers. 2021;13:4344.","journal-title":"Cancers"},{"key":"2161_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/wics.1549","volume":"13","author":"M Tayefi","year":"2021","unstructured":"Tayefi M, Ngo P, Chomutare T, Dalianis H, Salvi E, Budrionis A, et al. Challenges and opportunities beyond structured data in analysis of electronic health records. WIREs Comput Stat. 2021;13:e1549.","journal-title":"WIREs Comput Stat"},{"key":"2161_CR47","unstructured":"Health Do. National strategy for accelerating genetic and genomic medicine in Ireland. In: H.S.E., editor. 2022."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02161-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02161-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02161-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:38:08Z","timestamp":1788460688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02161-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":47,"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1038\/s41431-026-02161-3","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CS McNevin reports grants from the HRB\/Wellcome Trust during the conduct of the study, and travel support from AstraZeneca, Takeda, MSK Pharma and Ipsen Ireland outside this study. K. Murphy reports travel support from Daiichi-Sankyo and Novartis. All other authors (P Murchan, A Hennessy, O Fitzpatrick, S O\u2019Toole, P Smyth, E Atkinson, G Thodi, C O\u2019Brien, T McDevitt and R Kalachand) declare no competing interests. A-M Baird reports personal honoraria from AstraZeneca, Johnson & Johnson, Medscape, and Roche; she held leadership roles in Lung Cancer Europe (mandate ended April 2025) and the Irish Lung Cancer Community, both supported by multiple pharmaceutical companies (payments to organisations); and she serves as an unpaid Steering Committee Member with Roche. N Coleman reports consulting, advisory or speaker roles with MSD\/Merck and Pfizer, and travel support from Pfizer and Novartis. S Finn reports advisory roles with Amgen, Illumina, and Pfizer (personal) and Roche (institutional); speaker roles with AstraZeneca and Takeda; and personal stock ownership in Revolution Medicines. B Doyle reports consulting fees from Roche, honoraria from Janssen and Illumina, travel support from Bayer and AstraZeneca and participation in a Roche advisory board. SG Gray reports research funding from Portage Biotech (outside this study), an annual honorarium from SpringerNature, and royalties from Academic Press (Elsevier). K Cadoo reports institutional grants from the Irish Cancer Society, MSD Ireland, Immunogen, Karyopharm Therapeutics, NRG Oncology, and Verastem; consulting fees, speaker honoraria, expert testimony, travel support, and advisory roles with multiple organisations including Nextcure, GSK Ireland, Ipsos, Fresh Perspectives Iqvia, MJH Life Sciences, AstraZeneca, MSD Ireland, Abbvie, Roche Ireland, Pfizer, Merck Scientific Advisory Board, Eisai and St Vincent\u2019s Health; and voluntary leadership roles with Arc Cancer Support Centres, the National Cancer Control Programme Ireland, and the National Centre for Pharmacoeconomics Ireland.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}